ulcerative colitis. Ulcerative colitis
Conditions
Interventions
Intervention 1: The intervention group will receive 1 g taurine every day for 8 weeks in addition to their routine treatment and the mentioned outcome will be evaluated at time zero and 8 weeks later.
Treatment - Drugs
Control group will receive routine treatment and the mentioned outcomes will be evaluated at time zero and 8 weeks later.
The intervention group will receive 1 g taurine every day for 8 weeks in addition to their routine treatment and the mentioned outcome will be evaluated at time zero and 8 weeks later.
Taurine is an
Sponsors
Vice Chancellor for research of Tabriz University of Medical Sciences (Liver and Gastrointestinal di
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: patients of both sex, who are recently diagnosed with ulcerative colitis and are being treated for a maximum of 1 month; or their disease is not controlled by routine treatments. Exclusion criteria:pregnant women; presence of signs and symptoms for less than 2 weeks; diagnosed with crohn's disease; patients who receive supplements; patients with systemic disease such as tumor or perforation; patients with other inflammatory disease or history of surgery
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease signs and symptoms. Timepoint: Prior to intervention and 8 weeks after intervention. Method of measurement: Standard questionaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| TNF-a (tumour necrosis factor a) serum concentration. Timepoint: Prior to intervention and 8 weeks after intervention. Method of measurement: ELISA.;Interleukin (IL)-6 serum concentration. Timepoint: Prior to intervention and 8 weeks after intervention. Method of measurement: ELISA.;C-Reactive Protein. Timepoint: Prior to intervention and 8 weeks after intervention. Method of measurement: Available and tested methods.;Erythrocyte sedimentation rate (ESR). Timepoint: Prior to intervention and 8 weeks after intervention. Method of measurement: Available and tested methods.;Interleukin (IL)-1b serum concentration. Timepoint: Prior to intervention and 8 weeks after intervention. Method of measurement: ELISA.;Taurine concentration in serum. Timepoint: Prior to intervention and 8 weeks after intervention. Method of measurement: HPLC.;Serum Albumin concentration. Timepoint: Prior to intervention and 8 weeks after intervention. Method of measurement: Available and tested methods.;Quality of life. Timepoint: Prior to intervention and 8 weeks after intervention. Method of measurement: Questionaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Simin Mashayekhi
Tabriz University of Medical Sciences
Outcome results
None listed